ANGLE plc, a liquid biopsy company, has announced the publication of breakthrough research by the University of New Mexico into the role of circulating tumour cell (CTC) gene expression in the progression of melanoma brain metastasis. The researchers used ANGLE's Parsortix system to harvest CTCs for analysis and concluded that gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient. In pre-clinical mouse models of melanoma brain metastasis, two cancer drugs were tested individually and together, and blood samples were analysed using the Parsortix system. The researchers found that using the two drugs together was the most effective therapeutic regime, reducing tumour burden, metastasis, and CTC count. This research provides further evidence of the capability of the Parsortix system to be used for the harvesting of CTCs for analysis in pre-clinical mouse models.

ANGLE CEO Andrew Newland commented on the use of CTC biomarkers in clinical trials, stating that it is a rapidly growing field enabling longitudinal monitoring of transcriptomic and proteomic changes. ANGLE can provide pharma customers with a complete range of services to support preclinical and clinical drug development, including standardised and validated protocols for analysing CTCs and the capability to deliver bespoke assays to identify drug targets and ascertain therapeutic efficacy.

The global market for preclinical clinical research organisations exceeded a valuation of US$5 billion in 2022 and is expected to achieve a 7.5% CAGR over the next 10 years due to increasing R&D expenditure on early-stage development combined with the growing number of drugs in preclinical development.

The peer-reviewed journal article on this research is published in the journal of Cancers and is available on ANGLE's website.

ANGLE plc is a world-leading liquid biopsy company with innovative CTC diagnostic solutions for use in research, drug development, and clinical oncology. The company's FDA cleared and patent-protected Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis, as well as full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses focus on diagnostic products and clinical services, including custom-made assay development and clinical trial testing for pharma. Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system.